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Abstract
Background: Systematic evaluations of the quality of research on a single prognostic biomarker are rare. We sought to
evaluate the quality of prognostic research evidence for the association of C-reactive protein (CRP) with fatal and nonfatal
events among patients with stable coronary disease.
Methods and Findings: We searched MEDLINE (1966 to 2009) and EMBASE (1980 to 2009) and selected prospective studies
of patients with stable coronary disease, reporting a relative risk for the association of CRP with death and nonfatal
cardiovascular events. We included 83 studies, reporting 61,684 patients and 6,485 outcome events. No study reported a
prespecified statistical analysis protocol; only two studies reported the time elapsed (in months or years) between initial
presentation of symptomatic coronary disease and inclusion in the study. Studies reported a median of seven items (of 17)
from the REMARK reporting guidelines, with no evidence of change over time. The pooled relative risk for the top versus
bottom third of CRP distribution was 1.97 (95% confidence interval [CI] 1.78–2.17), with substantial heterogeneity (I2 = 79.5).
Only 13 studies adjusted for conventional risk factors (age, sex, smoking, obesity, diabetes, and low-density lipoprotein
[LDL] cholesterol) and these had a relative risk of 1.65 (95% CI 1.39–1.96), I2 = 33.7. Studies reported ten different ways of
comparing CRP values, with weaker relative risks for those based on continuous measures. Adjusting for publication bias
(for which there was strong evidence, Egger’s p,0.001) using a validated method reduced the relative risk to 1.19 (95% CI
1.13–1.25). Only two studies reported a measure of discrimination (c-statistic). In 20 studies the detection rate for
subsequent events could be calculated and was 31% for a 10% false positive rate, and the calculated pooled c-statistic was
0.61 (0.57–0.66).
Conclusion: Multiple types of reporting bias, and publication bias, make the magnitude of any independent association
between CRP and prognosis among patients with stable coronary disease sufficiently uncertain that no clinical practice
recommendations can be made. Publication of prespecified statistical analytic protocols and prospective registration of
studies, among other measures, might help improve the quality of prognostic biomarker research.
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Introduction
What Is the Problem?
Robust research evidence on the prognostic value of circulating
biomarkers is important for translational medicine and clinical
decision making, but there are concerns about the quality of such
evidence [1], largely based on studies in the field of cancer.
Systematic reviews and meta-analyses across multiple cancer
biomarkers [2–4] have found biases arising from selection of
studies for publication, or selection of findings for inclusion within
published studies. There have been few evaluations of the quality
of evidence focussing on a single biomarker [5]. It is not known the
extent to which such biases threaten validity of putative prognostic
biomarkers among people with cardiovascular disease, because of
a lack of large scale evaluations. Indeed in healthy population
studies of cardiovascular disease onset [6], reliable associations
largely free of such biases with a range of biomarkers have been
demonstrated. We studied C-reactive protein (CRP) in the
prognosis of stable coronary artery disease because it is the most
widely investigated (.100 studies) novel prognostic biomarker in
such patients [7], and therefore the research might be expected to
have reached reliable conclusions. Furthermore, there is clinical
uncertainty as to whether to measure CRP, with US [8] and
European [9] clinical practice guidelines recommending measure-
ment, but clinical practice varying widely [10].
Objectives
In evaluating the quality of published evidence on CRP in the
prognosis of patients with stable coronary disease we carried out a
systematic review, meta-analysis, and meta-regression [11,12] with
five specific objectives: (i) To determine the quality of study
reporting based on a systematic review. In the absence of agreed
criteria for measuring the quality of reporting we extended
previous efforts [3], and operationalised reporting guidelines for
tumour markers [12] into 17 items. A particular concern of ours
[1], notably absent from reporting guidelines, was whether studies
reported a reference to a study protocol or prespecified statistical
analytic protocol; (ii) To determine the extent to which any
association of CRP on prognosis was independent of established
prognostic factors. Unlike many cancers, cardiovascular disease
has numerous established markers of prognosis that are also
associated with aetiology, and CRP is a good example of a
prognostic biomarker that is highly correlated with these (smoking,
diabetes, obesity, lipids, and other markers of inflammation, such
as fibrinogen) [13,14]. The impact of biases in incomplete
adjustment for established risk factors has seldom been assessed
in large meta-analyses of prognostic biomarkers; (iii) To determine
the presence and magnitude of bias arising from small studies.
While previous meta-analyses have highlighted that publication
bias exists, here we use recently validated methods to assess the
potential magnitude of such biases [15]; (iv) To explore sources of
heterogeneity, particularly to assess whether aspects of study
design or reporting influenced the summary estimate of effect; (v)
To determine the extent to which papers report the ability of CRP
to discriminate patients who do and do not experience subsequent
events. Reporting such data has recently been recommended [16],
but it is not known how commonly it is reported.
Methods
Search for Eligible Papers and Inclusion Criteria
We included any prospective observational study (observational
cohort studies, prospective nested case control studies, observa-
tional data drawn from randomised controlled trials) that reported
risk of subsequent events among patients with stable coronary
disease in relation to measured CRP values. Eligible studies had to
include patients with stable coronary disease, defined as clinically
diagnosed angina pectoris or angiographic disease, or a history of
previous acute coronary syndrome at least 2 wk prior to CRP
measurement. We excluded studies where CRP was measured
only during an admission with an acute coronary syndrome, or
only after a coronary procedure, but before discharge. Eligible
outcome events were defined as coronary (coronary death, sudden
cardiac death, acute nonfatal myocardial infarction, primary
percutaneous coronary intervention, unplanned emergency ad-
missions with unstable angina), cardiovascular (where coronary
events were reported in combination with heart failure, stroke, or
peripheral arterial disease), and all cause mortality alone. We did
not exclude any studies on the basis of methodological standards,
sample size, duration of follow-up, publication year, or language of
publication. We searched MEDLINE (PubMed) between 1966
and 25 November 2009 and EMBASE between 1980 and 17
December 2009 databases using a strategy developed with an
expert librarian based on terms for coronary disease (from the
Cochrane Library of systematic reviews and protocols), prognostic
studies [17], and CRP. Three reviewers (NKF, JD, KM) reviewed
article titles and abstracts for eligibility and obtained full text
articles where eligibility was definite or unclear (see Figure S1).
Data Extraction for Systematic Review
The two reviewers independently abstracted data from eligible
articles (n = 116) using a predefined coding protocol. Non-English
articles were translated (n = 4). Individual item disagreement
between the two reviewers was resolved by consensus or, rarely,
adjudication by a third reviewer (HH). We extracted information
on year of publication, year of study start, number of patients at
baseline that were included in the analysis, their mean age and
percent women, the baseline coronary morbidity (proportion with
stable angina, angiographic disease, or previous myocardial
infarction), average levels of biomarker at baseline (either mean
[SD] or median [interquartile (IQR) range]) in the whole sample
and separately among those who did and did not subsequently
experience an outcome event, and type of high sensitivity CRP
assay, follow-up duration, the number and type (coronary,
cardiovascular, and all cause mortality) of outcome events (from
which the crude annual risk was calculated).
Data Extraction for Quality of Study Reporting
We developed closed-ended questions to operationalise prog-
nostic biomarker reporting guidelines [12] and extracted details on
17 items (see Table S1) relating to prespecified research question,
population at start and end of follow up, biomarker measurement,
outcome assessment, confounder measurement, and analytic
choices.
Data Extraction for Relative Risks
We extracted the reported relative risk, odds ratio or hazard
ratio, and 95% confidence intervals (CIs) from each study. Where
one study had multiple eligible articles or one article reported
multiple relative risks we extracted the relative risks for the most
specific coronary outcome event (according to the hierarchy
coronary, cardiovascular, all cause mortality) with the largest
number of adjustment variables. Where available we extracted
separate relative risk estimates with different degrees of confound-
er adjustment for the following prespecified conventional risk
factors (age, sex, smoking status, obesity, diabetes, and one or
more lipid variables [from total cholesterol, LDL cholesterol, HDL
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cholesterol, trigylcerides], and inflammatory markers [fibrinogen,
IL-6, white cell count]).
Statistical Analysis
We converted the reported relative risk estimates onto a
standard scale of effect, comparing the highest third with the
lowest third of the CRP distribution, in essence giving an estimate
per 2.18 SD units of CRP where 2.18 is the difference in the
means of the top and bottom third of the standard normal
distribution [18]. The reported comparisons included continuous
measures (per SD, tertile, quartile, unit [mg/l] on original or log
10 scale), equal size groups (top versus bottom with group size
50%, 33%, or 25% for 2, 3, and 4 groups, respectively), unequal
size groups (top versus bottom; 2 groups, 3 groups defined by cut-
points), as well as measures on both log-transformed and
untransformed CRP scales. The scaling methods assume that
CRP is log normally distributed and that the association with
disease risk is log-linear; both these assumptions have empirical
support in healthy population studies of CRP [19,20]. For two
equal groups the difference in means is 1.59 SD units and we used
a scaling factor of 1.37 (2.18/1.59). For four and five groups we
used a scaling factor of 2.18/2.54 and 2.18/2.80, respectively, i.e.,
the difference in means between the top and bottom tertile in each
case under the assumption of log normality for CRP. Unequal
groups required study-specific scaling factors, which were
calculated as 2.18/x where x is the difference in means between
the unequal groups. The differences were found by simulating one
million observations from the distribution used to report the
comparison (i.e., normal or log normal). For normally transformed
CRP, relative risks reported per standard deviation used a scaling
factor of 2.18 and relative risks reported per unit were converted
first to a SD change, using the study specific SD and thence to
tertiles. For untransformed CRP, relative risks reported per
standard deviation were scaled using the study-specific difference
in means between the upper and lower tertiles and the SD, and
those reported per mg/l were scaled using the difference in means
alone.
Statistical Methods for Meta-analysis and
Meta-regression
For each study, the relative risk estimate and its corresponding
standard error were transformed to their natural logarithms to
stabilise the variance and to normalise the distributions. Summary
relative risk estimates and their 95% CIs were estimated from a
random effects model that considers both within- and between-
study variation [21]. Statistical heterogeneity among studies was
evaluated using the I2 statistic [22].
Small study (including publication) bias was assessed with
contour-enhanced funnel plots (i.e., a plot of study relative risk
estimate against precision, with contours representing varying
levels of statistical significance), by Begg’s adjusted rank correlation
test, and by Egger’s regression asymmetry test [23,24]. We used
previously investigated methods to adjust the meta-analyses for the
potential impact of publication bias (see Table S3) [25]. These
included; (i) ‘‘trim and fill,’’ an iterative nonparametric method
using a rank-based data augmentation technique to account for
asymmetry in the funnel plot. Both the ‘‘trimming’’ of asymmetric
studies, for which there are no counterparts, and the revised
pooled estimate after ‘‘filling’’ (or imputing) these counterparts can
be based on either a fixed or random effects meta-analysis model.
Models considered here use either fixed or random effects models
for both components, or fixed effect model to ‘‘trim’’ and random
effects to ‘‘fill.’’ (ii) Weighted regression-based methods, which are
extensions of Egger’s regression asymmetry test [24,25] and
regress the outcome against a measure of study precision (standard
error, variance, or sample size), weighted by either the reciprocal
of either the total variance or the variance of the proportion of the
number of events in a study, in order to predict the effect size in a
(hypothetically) infinitely large study as a pooled estimate adjusted
for publication bias. These meta-regression models can either be
fixed effect or random effects models, or can allow for between-
study variability via a dispersion parameter. (iii) Conditional
regression-based methods, in which a test for small study bias is
performed first, and then if appropriate, regression-based methods
(as previously described above) are used to adjust the observed
effect size [25]. A quadratic version of the original Egger
regression test (using the variance rather than the standard error)
and including allowing for between-study variability via a
dispersion parameter has been shown in both simulation [25]
and empirical [15] studies to out-perform other approaches.
To explore other potential sources of study heterogeneity, we
employed a random effects meta-regression model that included
study level continuous or categorical covariates. Assumptions of
normality, independence, and homogeneity of residuals were
verified via diagnostic plots.
Discrimination
We calculated the detection rate at different false positive rates
by constructing the log-normal distributions of CRP separately for
those with and without outcome events using previously reported
methods [26,27]. Calculating the detection rate for false positive
rates from 0 to 100 then yields a receiver operating characteristic
(ROC) curve for the outcome group, from which c-statistics can be
calculated using the trapezium rule. Confidence intervals for the
ROC curves and detection rate at the 10% false positive rate were
obtained using large sample properties of binormal ROC curves
[28] and pooled estimates of both the c-statistic and detection rate
were subsequently obtained by random effects meta-analysis of the
study-specific c-statistics and detection rates. All analyses were




We identified 1,566 articles of which 83 studies fulfilled our
inclusion criteria (Figure S1) and are summarised in the systematic
review (Table S1). There were a total of 61,684 patients and 6,485
outcome events in these studies (median per study of 53 [range 4–
570]). Of these 83 studies, 72 had a unique article, and 11 were
selected from studies that had multiple eligible articles reporting
different CRP effects (see Table S1), but only one was included in
the meta-analysis according to the rules described under ‘‘data
extraction.’’ The mean age of patients across studies was a median
(IQR) of 62.4 y (60.0–65.3 y). The median (IQR) proportion of
women in studies was 24.9 (19–29). No studies reported stable
angina as the sole initial presentation; the median (IQR)
prevalence of previous myocardial infarction was 39% (26–50).
The proportion of stable patients was 100% in 14 studies, median
(IQR) of 49.8% (27.7%–67.8%) in 24 studies, and not stated in the
remainder.
Quality of Study Reports
The median (IQR) number of study quality items reported was
7 (6–8) out of a possible 17 and did not change between 1997 and
2009, and was not associated with study size (correlation
coefficient of 0.18, p = 0.11) (Figure 1). More than 80% of studies
reported details of the healthcare setting, exclusion criteria, assay
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type, and manufacturer. Two studies referred to a study protocol,
but no studies referred to a statistical analytic protocol. Two
studies reported the time elapsed between first lifetime presenta-
tion with coronary disease and assessment of CRP. Ten different
types of comparisons were used for presenting the relative risks
(five based on continuous CRP measures, three with equal sized
groups, and two with unequal sized groups [one two-group and
one three-group comparison]); the rationale for choosing these
groups was stated in 32.5% of studies.
Meta-analysis Forest Plot
The pooled relative risk from the random effects model of top
versus bottom third of CRP using the most highly adjusted study
estimate was 1.97 (95% CI 1.78–2.17) (Figure 2). There was
marked heterogeneity, with an I2 of 79.5% (95% CI 75.1–82.8).
Among the 13 studies that adjusted for conventional risk factors
(age, sex, smoking, obesity, diabetes, and low-density lipoprotein
[LDL] cholesterol), the relative risk was 1.65 (95% CI 1.39–1.96),
with a lower I2 of 33.7 (95% CI 0.0–64.6). Only three of these
studies adjusted, in addition, for fibrinogen or other inflammatory
markers and yielded a relative risk of 1.52 (1.25–1.85). The eight
studies that adjusted for one or more markers of inflammation,
irrespective of adjustment for conventional factors, yielded a
relative risk of 1.99 (95% CI 1.45–2.72). Among the 25 studies
reporting separate adjustments for age and sex only and for at
least one (median 2) conventional risk factor the relative risk for
CRP was attenuated by 39%, from 2.44 (95% CI 1.95–3.05) to
1.88 (95% CI 1.55–2.26), respectively. The median (IQR)
number of adjustments not including the conventional risk
factors was 4 (2–7), encompassing 78 unique risk factors (with
hypertension being the most common adjustment variable,
appearing in 28 studies).
Publication Bias
The funnel plot was markedly asymmetrical with less precise
(smaller) studies reporting higher relative risks than larger studies
(Egger’s test, p,0.001 and Begg’s rank correlation test, p = 0.001)
(Figure 3). Adjustment for the extent of publication bias reduced
the estimates to between 1.03 (95% CI 0.99–1.07) and 1.63 (95%
CI 1.47–1.79), depending on the method used (see Table S2). The
quadratic version of the Egger test gave an adjusted estimate for
the effect of CRP of 1.19 (95% CI 1.13–1.25). Using this test, there
was some evidence that the publication bias was greater for studies
reporting multivariate adjustments compared to those reporting
only a minimally adjusted estimate (test for interaction, p,0.0001).
Meta-regression
Univariate random effects meta-regression analyses identified
four study-level covariates that were associated with the pooled
relative risk: definition of comparison group, the number of
adjustment variables, the (log) number of events (p,0.01), and the
proportion of patients with stable coronary disease (p = 0.02)
(Figure 4). Studies originally reporting unequal CRP groups
reported stronger effects than those reporting CRP on a
continuous scale. Studies reported a median (IQR) of 6 (4–10)
adjustment variables, and for each additional adjustment variable
the relative risk decreased by 3%. The relative risk was 1.61
among studies with more than the median number of outcome
events (n= 53 events), and 3.28 for smaller studies. The relative
risk was 1.47 among studies confined to stable coronary disease,
2.23 in studies with a median of 48.5% stable patients, and 1.96 in
the studies in which this proportion was not stated. There was no
evidence that the CRP effect differed according to other
continuous study level covariates (age, percent women, CRP
level, percent on statins, follow-up duration, study start year,
Figure 1. Quality of individual study reports (n=17 items, n=83 studies), based on the REMARK guidelines [11]. Definitions of each
item are given in Table S2.
doi:10.1371/journal.pmed.1000286.g001
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Figure 2. Forest plot of the effect of CRP on prognosis among patients with stable coronary disease. Studies are grouped according to
the extent of adjustment for conventional risk factors.
doi:10.1371/journal.pmed.1000286.g002
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number of quality items reported) or to the categorical covariates
(event type, type of relative risk). For presentation purposes the
meta-regression forest plot is displayed for subgroups, with groups
subsequently analysed in the meta-regression chosen for the
categorical covariates and continuous covariates split above and
below their respective median values. The regression coefficient,
associated standard error and the I2 value, however, were obtained
from random effects meta-regression. The substantial heterogene-
ity in the meta-analysis remained largely unchanged in the meta-
regression, reflected in an I2 that stayed at around 80% and a
stable random effect variance.
Discrimination
Only two studies reported the area under the ROC curve or
equivalent c-statistic (Figure 5). Nineteen studies reported average
CRP values separately among those with and without events
enabling calculation of discrimination performance. We found
that selecting the cut-off value of CRP that gives a 10% false
positive rate (1-specificity), gave a detection rate (sensitivity) of
31% (range 6%–63%) when CRP was used alone as a screening
test. Our conclusions on discrimination were based on 20 studies
(2,374 events); however, the fact that these did not differ from the
other studies in terms of their reported relative risks, (p = 0.49), and
mean number of patients (697 versus 758, p = 0.97), and that the
findings were in line with those reported for aetiologic studies,
suggests that these findings are likely to be representative.
Discussion
In one of the largest (83 studies reporting over 61,000 patients)
and most detailed, to our knowledge, evaluations of a single
prognostic biomarker, we found the absence of prespecified
statistical analytic protocols, publication bias so marked that it
could potentially explain much of the association, and multiple
types of reporting biases. These biases preclude firm conclusions
about the magnitude and independence of the association between
higher CRP levels and higher risk of subsequent death and
nonfatal cardiovascular events. Taken together with evidence of
biases in prognostic biomarker research in cancer [4,5,29], stroke
[30], trauma [31], and musculoskeletal disorders [32,33], there is a
case for changing the way this type of research is designed and
reported.
Quality of Reporting of Primary Studies
Arguably the most fundamental concern was that 0 studies
referred to a prespecified statistical analytic protocol. Indeed only
two studies referred to any kind of protocol. Thus it is difficult to
know what the specific research objectives were at the start of
cohort recruitment, at the time of CRP measurement, or at the
onset of the statistical analysis. The rationale for comparison group
definition, confounder selection, and other analytic choices, even
when stated, may have been made after comparing the results of
different analytic approaches. Choosing which results to select for
presentation may introduce a bias towards ‘‘positive’’ findings.
Descriptions of study populations in the included studies were
poor and potentially biased. Only two studies reported the ‘‘stage’’
of the disease, here operationalised as the duration since initial
presentation [34]. Although all studies included patients with
stable coronary disease, the magnitude of association between
CRP and outcomes was greater among studies in which the
percentage of stable patients was not stated.
There are no agreed comprehensive criteria for measuring the
quality of study reports. The REMARK reporting guidelines for
tumour prognostic markers provide a useful start, but are not
currently in a form that lend themselves to measurement, and omit
reference to statistical analytic protocols. We operationalised the
REMARK guidelines and found that studies reported an average
of seven of 17 quality items [12]. There was no increase in the
average number of items reported over the 13 y since the first
publication. Previous systematic reviews have assessed a smaller set
of reporting items (seven items [3], three items [35]). In a
systematic review of 117 studies of one prognostic biomarker, P53
Figure 3. Funnel plot with contours showing different levels of study significance.
doi:10.1371/journal.pmed.1000286.g003
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Figure 4. Meta-regression of categorical and continuous study level covariates.
doi:10.1371/journal.pmed.1000286.g004
Figure 5. Detection rates at 10% false positive rate and c-statistic for individual studies, and pooled ROC curve.
doi:10.1371/journal.pmed.1000286.g005
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in bladder cancer, only 34 studies reported sufficient data to be
included in a meta-analysis [5].
Independence of CRP Effect
We graphically depict the incomplete approach to confounder
adjustment. Only 13 studies adjusted for a basic set of
conventional risk markers and only eight studies adjusted for
fibrinogen or other measure of inflammation. Thus the available
evidence does not systematically evaluate the independence of the
CRP prognosis association from potential confounders, and the
extent of residual confounding is not known. Such adjustments are
likely to be important because: first, attenuation of the relative risk
between minimally adjusted and adjusted models was about 39%
in the 25 studies reporting this comparison. Second, studies
including a higher number of adjustment variables reported lower
relative risks, with each additional variable being associated with
about a 3% reduction of the relative risk.
Publication Bias
Not only did we find strong evidence that publication bias was
operating (most studies were small with a median of 53 events per
study, and smaller studies were more likely to report higher
relative risks), but we quantified the possible magnitude and
impact of this bias. We have previously identified through
simulation studies [25], and empirical [15] studies—where a gold
standard of unpublished data is available—a method for adjusting
for publication bias that outperforms others. This method, a
quadratic version of the Egger regression test, attenuated the effect
of CRP by 81%. However, all methods of adjustment produced
attenuated results, with levels of attenuation ranging from 28% to
96%. It is worth noting that the funnel plot asymmetry is present
even for larger studies. The degree of the bias arising from
nonpublication calls into question the strength of any association
between CRP and outcome.
Discrimination and Prediction
American Heart Association guidelines [16] recommend reporting
measures of discrimination but only two studies in our review did.
This reporting of risk prediction is of wide clinical interest because
stable coronary disease has a high annual risk of fatal and nonfatal
acute coronary syndromes of between 2% [36] and 5% [37,38] and
affects an increasing number of people [39] as the population ages
and survival from acute coronary syndromes improves.
Because of the lack of published protocols, we do not know
whether other studies carried out, but elected not to report, such
analyses. Based on the 20 studies reporting CRP distributions
among those with and without events, CRP on its own detected
only 31% of patients who would subsequently experience events at
a 10% false positive rate. We found a c-statistic of 0.61, similar to
the 0.65 observed in healthy population studies [6]. Given the
magnitude of the CRP relative risk, and that CRP is correlated
with some of the factors (e.g. white cell count, glucose) in existing
scores, it seems unlikely that CRP would add substantially to the
discrimination achieved by standard clinical factors among
patients with stable coronary disease [40,41]. Even if it does add
predictive information, CRP may not be cost-effective [7,42].
Comparison with Healthy Population Studies
By contrast with the evidence among patients with coronary
disease, the quality of evidence in healthy populations (aetiologic)
[6,19,43–47] is not subject to the same concerns. Sufficiently
unbiased and precise estimates of CRP effect have been obtained
that allow assessment of confounding in mendelian randomisation
approaches, which in turn have questioned the role of CRP in
disease onset. A causal role in disease progression is still possible
for CRP if, for example, it were associated with thrombosis and
necrosis, rather than the development of atherosclerosis. The
populations in our systematic review, compared to healthy
population studies [6], evaluated the role of higher initial CRP
levels (2.3 versus 1.28 mg/l), shorter follow up periods (median
2.5 y versus 3–20 y). and higher annual risk of events (5.5% versus
,1%). Observational studies of other markers, such as body mass
index are known to exhibit different aetiologic and prognostic
effects [48].
Limitations
The main limitation is that we studied what authors and journal
editors select for reporting and not study quality per se. However
in many instances it is likely that there is a strong correlation. It is
also possible that we missed published studies, although we suspect
that the higher quality studies would be more likely to be detected.
Research Implications
We previously outlined ten steps for improving prognosis
research [1], which include the need for prospective study
registration, publication of design and analytic protocols, and
prospective individual participant data meta-analysis. Pooling data
from a subset of larger, higher quality, more homogeneous studies
in order to make better adjustments for confounders and further
investigate discrimination (e.g., with net reclassification improve-
ment measures) is feasible in such clinical datasets [49]. But our
review suggests that identifying such a subset of studies may not be
easy, and there is a need for new clinical cohorts. Better reporting
is required and the existing guidelines are a start [12,50], but these
require development across disease areas and formalisation into
data extraction tools. The CRP–prognosis literature may be
summarised as early (phase 1) stage, in which investigators aim to
discover and report possible associations [51]. There is a need to
move to phase 2 in which these associations are more rigorously
evaluated. Such better quality observational evidence is an
important basis for prioritizing other methods of addressing
confounding [52] such as ‘‘mendelian randomisation’’ [13,43–47]
and randomisation to specific biomarker lowering agents [53].
Clinical Implications
Our findings suggest that clinical guidelines [8,9] should change
their recommendations. The available evidence supports a
negative recommendation, i.e., that CRP should not be routinely
measured among patients with stable coronary disease to quantify
prognosis or to guide interventional therapies. Our findings
explicitly challenge the statement for healthcare professionals
made by the Centers for Disease Control that measuring CRP is
both ‘‘useful’’ and ‘‘independent’’ as a marker of prognosis.
Furthermore, there is a need for a clear framework in which
guideline developers can evaluate the type and quality of evidence
necessary to make clinical practice recommendations on prognos-
tic biomarkers.
Conclusion
The quality of published evidence on CRP and prognosis in
stable coronary disease is poor and is not sufficient to recommend
routine measurement of this biomarker. This review, and others in
cancer, constitutes an indictment of the research culture in
prognostic biomarkers, and highlights areas for change, the most
fundamental of which is the need to register studies along with
their analytic protocols.
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Editors’ Summary
Background. Coronary artery disease is the leading cause
of death among adults in developed countries. With age,
fatty deposits called atherosclerotic plaques coat the walls of
the arteries, the vessels that carry blood to the body’s
organs. Because they narrow the arteries, atherosclerotic
plaques restrict blood flow. If plaques form in the arteries
that feed the heart, the result is coronary artery disease, the
symptoms of which include shortness of breath and chest
pains (angina). If these symptoms only occur during exertion,
the condition is called stable coronary artery disease.
Coronary artery disease can cause potentially fatal heart
attacks (myocardial infarctions). A heart attack occurs when a
plaque ruptures and a blood clot completely blocks the
artery, thereby killing part of the heart. Smoking, high blood
pressure, high blood levels of cholesterol (a type of fat),
diabetes, and being overweight are risk factors for coronary
artery disease. Treatments for the condition include lifestyle
changes and medications that lower blood pressure and
blood cholesterol. Narrowed arteries can also be widened
using a device called a stent or surgically bypassed.
Why Was This Study Done? Clinicians can predict
whether a patient with coronary artery disease is likely to
have a heart attack by considering their risk factors. They
then use this ‘‘prognosis’’ to help them manage the patient.
To provide further help for clinicians, researchers are trying
to identify prognostic biomarkers (molecules whose blood
levels indicate how a disease might develop) for coronary
artery disease. However, before a biomarker can be used
clinically, it must be properly validated and there are
concerns that there is insufficient high quality evidence to
validate many biomarkers. In this systematic review and
meta-analysis, the researchers ask whether the evidence for
an association between blood levels of C-reactive protein
(CRP, an inflammatory protein) and subsequent fatal and
nonfatal events affecting the heart and circulation
(cardiovascular events) among patients with stable
coronary artery disease supports the routine measurement
of CRP as recommended in clinical practice guidelines. A
systematic review uses predefined criteria to identify all the
research on a given topic; a meta-analysis is a statistical
method for combining the results of several studies.
What Did the Researchers Do and Find? The researchers
identified 83 studies that investigated the association
between CRP levels measured in people with coronary
artery disease and subsequent cardiovascular events. Their
examination of these studies revealed numerous reporting
and publication short-comings. For example, none of the
studies reported a prespecified statistical analysis protocol,
yet analyses should be prespecified to avoid the choice of
analytical method biasing the study’s results. Furthermore,
on average, the studies only reported seven of the 17
recommended items in the REMARK reporting guidelines,
which were designed to improve the reporting quality of
tumor biomarker prognostic studies. The meta-analysis
revealed that patients with a CRP level in the top third of
the distribution were nearly twice as likely to have a
cardiovascular event as patients with a CRP in the bottom
third of the distribution (a relative risk of 1.97). However, the
outcomes varied considerably between studies
(heterogeneity) and there was strong evidence for
publication bias—most published studies were small and
smaller studies were more likely to report higher relative
risks. Adjustment for publication bias reduced the relative
risk associated with high CRP levels to 1.19. Finally, nearly all
the studies failed to calculate whether CRP measurements
discriminated between patients likely and unlikely to have a
subsequent cardiovascular event.
What Do These Findings Mean? These findings suggest
that, because of multiple types of reporting and publication
bias, the size of the association between CRP levels and
prognosis among patients with stable coronary artery
disease is extremely uncertain. They also suggest that CRP
measurements are unlikely to add anything to the
prognostic discrimination achieved by considering blood
pressure and other standard clinical factors among this
patient group. Thus, the researchers suggest, the
recommendation that CRP measurements should be used
in the management of patients with stable coronary artery
disease ought to be removed from clinical practice
guidelines. More generally, these findings increase
concerns about the quality of research into prognostic
biomarkers and highlight areas that need to be changed, the
most fundamental of which is the need to preregister studies
on prognostic biomarkers and their analytic protocols.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000286.
N The MedlinePlus Encyclopedia has pages on coronary
artery disease and C-reactive protein (in English and
Spanish)
N MedlinePlus provides links to other sources of information
on heart disease
N The American Heart Association provides information for
patients and caregivers on all aspects of cardiovascular
disease, including information on the role of C-reactive
protein in heart disease
N Information is available from the British Heart Foundation
on heart disease and keeping the heart healthy
N Wikipedia has pages on biomarkers and on C-reactive
protein (note that Wikipedia is a free online encyclopedia
that anyone can edit; available in several languages)
N The EQUATOR network is a resource center for good
reporting of health research studies
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